The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Benign Prostatic Hyperplasia (BPH) Drugs Market Research Report 2024
Synopsis
BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.
The global Benign Prostatic Hyperplasia (BPH) Drugs market was valued at US$ 3329.5 million in 2023 and is anticipated to reach US$ 4195.1 million by 2030, witnessing a CAGR of 3.3% during the forecast period 2024-2030.
North America is the largest consumption place, with a consumption market share nearly 38% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 27.6%. Market competition is intense. Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
This report aims to provide a comprehensive presentation of the global market for Benign Prostatic Hyperplasia (BPH) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Benign Prostatic Hyperplasia (BPH) Drugs.
Report Scope
The Benign Prostatic Hyperplasia (BPH) Drugs market size, estimations, and forecasts are provided in terms of sales volume (M Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Benign Prostatic Hyperplasia (BPH) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Benign Prostatic Hyperplasia (BPH) Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Mylan
Novartis
Merck
Segment by Type
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others
Segment by Application
Hospitals
Drugstores
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Benign Prostatic Hyperplasia (BPH) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Benign Prostatic Hyperplasia (BPH) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.
The global Benign Prostatic Hyperplasia (BPH) Drugs market was valued at US$ 3329.5 million in 2023 and is anticipated to reach US$ 4195.1 million by 2030, witnessing a CAGR of 3.3% during the forecast period 2024-2030.
North America is the largest consumption place, with a consumption market share nearly 38% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 27.6%. Market competition is intense. Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
This report aims to provide a comprehensive presentation of the global market for Benign Prostatic Hyperplasia (BPH) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Benign Prostatic Hyperplasia (BPH) Drugs.
Report Scope
The Benign Prostatic Hyperplasia (BPH) Drugs market size, estimations, and forecasts are provided in terms of sales volume (M Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Benign Prostatic Hyperplasia (BPH) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Benign Prostatic Hyperplasia (BPH) Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Mylan
Novartis
Merck
Segment by Type
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others
Segment by Application
Hospitals
Drugstores
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Benign Prostatic Hyperplasia (BPH) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Benign Prostatic Hyperplasia (BPH) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Benign Prostatic Hyperplasia (BPH) Drugs Market Overview
1.1 Product Overview and Scope of Benign Prostatic Hyperplasia (BPH) Drugs
1.2 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type
1.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Alpha-Blocker
1.2.3 Phosphodiesterase Type-5 Inhibitors
1.2.4 Others
1.3 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application
1.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Estimates and Forecasts
1.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2019-2030
1.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales 2019-2030
1.4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Benign Prostatic Hyperplasia (BPH) Drugs Market Competition by Manufacturers
2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Product Type & Application
2.7 Benign Prostatic Hyperplasia (BPH) Drugs Market Competitive Situation and Trends
2.7.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Benign Prostatic Hyperplasia (BPH) Drugs Players Market Share by Revenue
2.7.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Benign Prostatic Hyperplasia (BPH) Drugs Retrospective Market Scenario by Region
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region: 2019-2030
3.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region: 2019-2024
3.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region: 2025-2030
3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2019-2030
3.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2019-2024
3.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2025-2030
3.4 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
3.4.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2030)
3.4.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
3.5.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2030)
3.5.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
3.7.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2030)
3.7.3 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2030)
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2024)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2025-2030)
4.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2019-2030)
4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2030)
4.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2024)
4.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2025-2030)
4.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2030)
5.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2024)
5.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2025-2030)
5.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2019-2030)
5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2030)
5.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2024)
5.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2025-2030)
5.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Eli Lilly
6.1.1 Eli Lilly Corporation Information
6.1.2 Eli Lilly Description and Business Overview
6.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.1.5 Eli Lilly Recent Developments/Updates
6.2 GlaxoSmithKline
6.2.1 GlaxoSmithKline Corporation Information
6.2.2 GlaxoSmithKline Description and Business Overview
6.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.2.5 GlaxoSmithKline Recent Developments/Updates
6.3 Astellas Pharma
6.3.1 Astellas Pharma Corporation Information
6.3.2 Astellas Pharma Description and Business Overview
6.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.3.5 Astellas Pharma Recent Developments/Updates
6.4 Sanofi
6.4.1 Sanofi Corporation Information
6.4.2 Sanofi Description and Business Overview
6.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.4.5 Sanofi Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Corporation Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 Abbott
6.6.1 Abbott Corporation Information
6.6.2 Abbott Description and Business Overview
6.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.6.5 Abbott Recent Developments/Updates
6.7 Allergan
6.6.1 Allergan Corporation Information
6.6.2 Allergan Description and Business Overview
6.6.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.7.5 Allergan Recent Developments/Updates
6.8 TEVA
6.8.1 TEVA Corporation Information
6.8.2 TEVA Description and Business Overview
6.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.8.5 TEVA Recent Developments/Updates
6.9 Mylan
6.9.1 Mylan Corporation Information
6.9.2 Mylan Description and Business Overview
6.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.9.5 Mylan Recent Developments/Updates
6.10 Novartis
6.10.1 Novartis Corporation Information
6.10.2 Novartis Description and Business Overview
6.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.10.5 Novartis Recent Developments/Updates
6.11 Merck
6.11.1 Merck Corporation Information
6.11.2 Merck Benign Prostatic Hyperplasia (BPH) Drugs Description and Business Overview
6.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.11.5 Merck Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Chain Analysis
7.2 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Benign Prostatic Hyperplasia (BPH) Drugs Production Mode & Process
7.4 Benign Prostatic Hyperplasia (BPH) Drugs Sales and Marketing
7.4.1 Benign Prostatic Hyperplasia (BPH) Drugs Sales Channels
7.4.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors
7.5 Benign Prostatic Hyperplasia (BPH) Drugs Customers
8 Benign Prostatic Hyperplasia (BPH) Drugs Market Dynamics
8.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Trends
8.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers
8.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges
8.4 Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
